Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
This research study is led by Dr. Joanna Luty.
Contact: Dawn DeMarinis, 413-794-4362
May 09, 2018
Cancer - Pediatric
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Ages Eligible for Study: 365 Days to 30 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Interventional (Clinical Trial), Randomized